Navigation Links
New Educational Tool for Understanding UC Flares
Date:5/18/2009

MARIETTA, Ga., May 18 /PRNewswire/ -- Ulcerative colitis (UC) is a chronic, inflammatory bowel disease (IBD) affecting half a million people in the United States, yet many patients don't always understand how to recognize or treat the symptoms associated with the disease.

Ulcerative colitis is an inflammation of the lining of the rectum and colon. The disease is marked by unpredictable "flares" when the inflammation causing the disease state spikes, causing stomach pain and bloody diarrhea. Up to 80 percent of UC patients suffer from flares. This highlights the need for patient, physician, and caregiver information.(1)

To provide that information, an educational brochure titled, Managing Flares and other IBD Symptoms, is now available from the Crohn's and Colitis Foundation of America (CCFA), made possible by an educational grant from Alaven Pharmaceutical LLC, makers of the topical UC flare treatment, ROWASA Kit* (mesalamine rectal suspension enema).

The brochure further defines the symptoms of flare-ups for both Crohn's** disease and UC and includes information on diet and lifestyle, the treatment options for overall maintenance of the diseases and flares specifically, questions patients should ask their doctor when flares occur and a flare symptom tracker.(2)

"We've learned from patients and physicians that there is a need for outreach about what people living with inflammatory bowel diseases should know about flares," said Dave Riccio, Product Manager, Alaven Pharmaceutical. "Working with the CCFA to provide patients with another tool to fight against UC flares will help educate them on how to effectively manage their disease and treat unwanted flare symptoms when they strike."

Gastroenterologists interested in providing the flare brochure to UC patients may request copies at www.flarefighter.com.

The brochure will also be made available to CCFA patient chapters across the country and can be downloaded at www.ccfa.org or via www.RowasaKit.com. Patients experiencing flares and who would like additional support services may also visit the CCFA's community website at www.ccfacommunity.org.

ROWASA is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis, or proctitis.

Full Prescribing Information available: www.ROWASAKit.com.

*Wipe is optional and not a required part of treatment

**ROWASA is not indicated for the treatment of Crohn's Disease.

(1) Tindall WN, Boltri JM, Wihelm SM. Mild-to-Moderate Ulcerative Colitis: Your role in patient compliance and health care costs. JMCP. 2007;13(7): S1-S15.

(2) Managing Flares and Other IBD Symptoms. CCFA. April 2009.


'/>"/>
SOURCE Alaven Pharmaceutical LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Educational initiatives improve quality of care delivery
2. Ann Marie DeMatteo Joins CME LLC as Vice President of Educational Initiatives, Drives Innovative Programming Approaches
3. IOF launches educational slide kit to enhance understanding of FRAX
4. New Jersey IT Services Firm to Host Educational Luncheon Event, EMR & Information Technology for the Specialty Medical Practice
5. Medifecta Healthcare Training Launches Website with Educational Resources and Online Training for Caregivers
6. Womens International Pharmacy Offers Free Educational Information About Bioidentical Hormone Replacement Therapy
7. HIPAApedia.com Goes Live - The First Dedicated Educational Community Wiki Aimed at Healthcare Information Professionals Interested in HIPAA Regulatory Issues and Solutions.
8. April is National Autism Awareness Month: LoJack Hosts Educational Podcast Featuring Panel of Experts Addressing Autism Issues
9. CERTPOINT Systems Partners with Medcom Trainex, Inc. to Offer Extensive Library of Healthcare Courses -- Professionals in Healthcare sector to benefit from online educational courses
10. Spotlight Baby Provides Parents with Educational Programs and Eco-Friendly Products to Support Babies in Reaching Their Full Developmental Potentials
11. Edifecs Launches First of a Series of Edifecs5010(TM) Migration Educational Webinars Addressing 5010 Migration Challenges, Opportunities and Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... Researchers can ... so routine. A fresh look at this technique may yield big benefits. Scientists ... reproducibility of experiments in a cell culture laboratory—and lessen the risk of contamination ...
(Date:5/23/2016)... ... May 23, 2016 , ... In light of ... reminds pet owners that intervening at the first sign of their pet overheating ... normal body mechanisms cannot keep the body’s temperature within a safe range. Considered ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Society for Women’s Health ... to move on from that role. , “No one in Washington led the way ... said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep gratitude to Phyllis ...
(Date:5/23/2016)... ... 2016 , ... Hadley Institute for the Blind and Visually ... or visually impaired, announces the election of Julie S. Tye as its next ... of Trustees retained Morris & Berger, a firm specializing in non-profit executive searches, ...
(Date:5/23/2016)... NY (PRWEB) , ... May 23, 2016 , ... ... the company’s top management team to meet the needs of its recent and ... to drive continued growth and business development across widening market segments. Max joined ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 23, 2016 Gamida Cell, a ... of cancer and orphan genetic diseases, announced today it ... million from the Israel Innovation Authority (formerly the Office ... Economy and Industry. The mission of the Israel Innovation ... industries, including science and technology, while stimulating economic growth. ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
(Date:5/20/2016)... 2016 - Revenue Forecasts ... Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine ... New Study Reveals Selling Opportunities and Revenue Prospects ... ,What is the future of biologics, especially new ... commercial analysis. Staying ahead in data and knowledge, ...
Breaking Medicine Technology: